title: A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.
abstract: Vortioxetine is approved for the treatment of major depressive disorder (MDD). This analysis aimed to develop pharmacokinetic (PK) and PK/Efficacy models to evaluate the exposure-response relationship for vortioxetine in patients with MDD. PK data from 10 MDD and two generalized anxiety disorder studies of vortioxetine (3160 patients), and efficacy data [Montgomery-Åsberg Depression Rating Scale (MADRS)] from seven MDD studies (2537 patients), were used for the development of PK and PK/Efficacy models. One- and two-compartment models were evaluated as structural PK models, and linear and nonlinear (Emax) models were used to describe the relationship between average vortioxetine concentration at steady-state (Cav) and change in MADRS score from baseline (ΔMADRS). The impact of selected covariates on the PK and efficacy parameters of vortioxetine was also investigated. PK of vortioxetine was best characterized by a two-compartment model with first-order absorption and elimination. Mean estimates for oral clearance (CL/F) and volume of distribution for the central compartment of vortioxetine were 42 L/hr and 2920 L. Creatinine clearance, height and geographic region had statistically significant effects on vortioxetine CL/F, but the effect of each of these covariates was not considered clinically relevant, as they lead to ±26% change in area under the curve or Cmax of vortioxetine. An Emax model best described the relationship between ΔMADRS and Cav. Half-maximal effective concentration (EC50) and Emax estimates were 24.9 ng/mL and 7.0. No identified covariates, except region, had clinically meaningful effects on vortioxetine efficacy. These PK/Efficacy models adequately characterized the vortioxetine exposure-response relationship.
authors.affiliation: Takeda Pharmaceuticals USA Inc., Deerfield, IL, USA.
authors.forename: Himanshu
authors.initials: H
authors.lastname: Naik
authors.affiliation: Takeda Pharmaceuticals USA Inc., Deerfield, IL, USA.
authors.forename: Serena
authors.initials: S
authors.lastname: Chan
authors.affiliation: Takeda Pharmaceuticals USA Inc., Deerfield, IL, USA.
authors.forename: Majid
authors.initials: M
authors.lastname: Vakilynejad
authors.affiliation: Takeda Development Center Americas Inc., Deerfield, IL, USA.
authors.forename: Grace
authors.initials: G
authors.lastname: Chen
authors.affiliation: H. Lundbeck A/S, Valby, Denmark.
authors.forename: Henrik
authors.initials: H
authors.lastname: Loft
authors.affiliation: Takeda Development Center Americas Inc., Deerfield, IL, USA.
authors.forename: Atul R
authors.initials: AR
authors.lastname: Mahableshwarkar
authors.affiliation: H. Lundbeck A/S, Valby, Denmark.
authors.forename: Johan
authors.initials: J
authors.lastname: Areberg
mesh_terms: D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D016014:Linear Models; D008954:Models, Biological; D017711:Nonlinear Dynamics; D010879:Piperazines / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D013440:Sulfides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D014018:Tissue Distribution; D000078784:Vortioxetine
chemical_list: D010879:Piperazines; D017367:Selective Serotonin Reuptake Inhibitors; D013440:Sulfides; D000078784:Vortioxetine